Immunotherapies | Pharmacor | G7 | 2014

The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in anticancer treatment since the advent of the cytokines. Their approvals dramatically altered the treatment landscape in their respective indications—prostate cancer and malignant melanoma—and laid the foundations for the re-emergence of immunotherapy as a key treatment strategy in oncology. A plethora of cancer immunotherapies are in development for multiple oncology indications and present a highly lucrative opportunity for immunotherapy developers.

Login to access report

launch Related Market Assessment Reports